137 related articles for article (PubMed ID: 35866797)
1. Long-term impact of certain coexisting extrahepatic unisystem and multisystem manifestations on trends in incidence of liver cirrhosis in treatment-naïve patients with chronic hepatitis C: A nested case-control study.
Wang CH; Ou SF; Tseng YT
Medicine (Baltimore); 2022 Jul; 101(29):e29697. PubMed ID: 35866797
[TBL] [Abstract][Full Text] [Related]
2. The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection.
Mahale P; Engels EA; Li R; Torres HA; Hwang LY; Brown EL; Kramer JR
Gut; 2018 Mar; 67(3):553-561. PubMed ID: 28634198
[TBL] [Abstract][Full Text] [Related]
3. Risk of diabetes in HIV-infected patients is associated with cirrhosis but not with chronic HCV coinfection in a French nationwide HIV cohort.
Provoost A; Dramé M; Cotte L; Cuzin L; Garraffo R; Rey D; Raffi F; Poizot-Martin I; Pugliese P; Bani-Sadr F;
Aliment Pharmacol Ther; 2018 Aug; 48(3):281-289. PubMed ID: 29901821
[TBL] [Abstract][Full Text] [Related]
4. Impact of Interferon-Free Direct-Acting Antivirals on the Incidence of Extrahepatic Malignancies in Patients with Chronic Hepatitis C.
Honma Y; Shibata M; Morino K; Koya Y; Hayashi T; Ogino N; Kusanaga M; Oe S; Miyagawa K; Abe S; Tabaru A; Harada M
Dig Dis Sci; 2023 Feb; 68(2):685-698. PubMed ID: 36100828
[TBL] [Abstract][Full Text] [Related]
5. Sustained virological response from interferon-based hepatitis C regimens is associated with reduced risk of extrahepatic manifestations.
Rossi C; Jeong D; Wong S; McKee G; Butt ZA; Buxton J; Wong J; Darvishian M; Bartlett S; Samji H; Yu A; Binka M; Alvarez M; Adu PA; Tyndall M; Krajden M; Janjua NZ;
J Hepatol; 2019 Dec; 71(6):1116-1125. PubMed ID: 31433302
[TBL] [Abstract][Full Text] [Related]
6. Insulin resistance and lichen planus in patients with HCV-infectious liver diseases.
Nagao Y; Kawasaki K; Sata M
J Gastroenterol Hepatol; 2008 Apr; 23(4):580-5. PubMed ID: 18397487
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort).
Hsu WF; Tsai PC; Chen CY; Tseng KC; Lai HC; Kuo HT; Hung CH; Tung SY; Wang JH; Chen JJ; Lee PL; Chien RN; Lin CY; Yang CC; Lo GH; Tai CM; Lin CW; Kao JH; Liu CJ; Liu CH; Yan SL; Bair MJ; Su WW; Chu CH; Chen CJ; Lo CC; Cheng PN; Chiu YC; Wang CC; Cheng JS; Tsai WL; Lin HC; Huang YH; Huang JF; Dai CY; Chuang WL; Yu ML; Peng CY
J Gastroenterol Hepatol; 2021 Oct; 36(10):2884-2892. PubMed ID: 33963615
[TBL] [Abstract][Full Text] [Related]
8. Impact of hepatitis C virus infection on long-term mortality after acute myocardial infarction: a nationwide population-based, propensity-matched cohort study in Taiwan.
Kuo SH; Hung WT; Tang PL; Huang WC; Yang JS; Lin HC; Mar GY; Chang HT; Liu CP
BMJ Open; 2018 Jan; 8(1):e017412. PubMed ID: 29374659
[TBL] [Abstract][Full Text] [Related]
9. Diabetes Mellitus Heightens the Risk of Hepatocellular Carcinoma Except in Patients With Hepatitis C Cirrhosis.
Yang JD; Mohamed HA; Cvinar JL; Gores GJ; Roberts LR; Kim WR
Am J Gastroenterol; 2016 Nov; 111(11):1573-1580. PubMed ID: 27527741
[TBL] [Abstract][Full Text] [Related]
10. Association of HCV with diabetes mellitus: an Egyptian case-control study.
Elhawary EI; Mahmoud GF; El-Daly MA; Mekky FA; Esmat GG; Abdel-Hamid M
Virol J; 2011 Jul; 8():367. PubMed ID: 21791087
[TBL] [Abstract][Full Text] [Related]
11. Risk of liver cirrhosis in patients with tuberculosis: a nationwide cohort study.
Peng YC; Lin CL; Hsu WY; Chang CS; Yeh HZ; Kao CH
Eur J Clin Invest; 2015 Jul; 45(7):663-9. PubMed ID: 25903030
[TBL] [Abstract][Full Text] [Related]
12. [Extrahepatic manifestations of chronic hepatitis C and their influence on response to treatment with pegylated interferon alfa-2a and ribavirin].
Fabri M; Ruzić M; Lendak D; Preveden T; Fabri I; Petrić V
Srp Arh Celok Lek; 2013; 141(5-6):320-4. PubMed ID: 23858800
[TBL] [Abstract][Full Text] [Related]
13. Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin.
Ng KJ; Tseng CW; Chang TT; Tzeng SJ; Hsieh YH; Hung TH; Huang HT; Wu SF; Tseng KC
Clin Interv Aging; 2016; 11():1035-41. PubMed ID: 27536084
[TBL] [Abstract][Full Text] [Related]
14. Human Immunodeficiency Virus/Hepatitis C Virus (HCV) Co-infected Patients With Cirrhosis Are No Longer at Higher Risk for Hepatocellular Carcinoma or End-Stage Liver Disease as Compared to HCV Mono-infected Patients.
Salmon-Ceron D; Nahon P; Layese R; Bourcier V; Sogni P; Bani-Sadr F; Audureau E; Merchadou L; Dabis F; Wittkop L; Roudot-Thoraval F;
Hepatology; 2019 Sep; 70(3):939-954. PubMed ID: 30569448
[TBL] [Abstract][Full Text] [Related]
15. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
[TBL] [Abstract][Full Text] [Related]
16. Analysis of hepatitis C virus (HCV) RNA in the lesions of lichen planus in patients with chronic hepatitis C: detection of anti-genomic- as well as genomic-strand HCV RNAs in lichen planus lesions.
Kurokawa M; Hidaka T; Sasaki H; Nishikata I; Morishita K; Setoyama M
J Dermatol Sci; 2003 Jun; 32(1):65-70. PubMed ID: 12788531
[TBL] [Abstract][Full Text] [Related]
17. Incidence and predictors of cardiovascular disease, chronic kidney disease, and diabetes in HIV/HCV-coinfected patients who achieved sustained virological response.
Leone S; Prosperi M; Costarelli S; Nasta P; Maggiolo F; Di Giambenedetto S; Saracino A; Di Pietro M; Gori A
Eur J Clin Microbiol Infect Dis; 2016 Sep; 35(9):1511-20. PubMed ID: 27272121
[TBL] [Abstract][Full Text] [Related]
18. Increased risk of hepatocellular carcinoma in chronic hepatitis C patients with new onset diabetes: a nation-wide cohort study.
Huang YW; Wang TC; Yang SS; Lin SY; Fu SC; Hu JT; Liu CJ; Kao JH; Chen DS
Aliment Pharmacol Ther; 2015 Oct; 42(7):902-11. PubMed ID: 26211742
[TBL] [Abstract][Full Text] [Related]
19. Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications.
Nahon P; Bourcier V; Layese R; Audureau E; Cagnot C; Marcellin P; Guyader D; Fontaine H; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Leroy V; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Dharancy S; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle C; Dao T; Benhamou Y; Pilette C; Silvain C; Christidis C; Capron D; Bernard-Chabert B; Zucman D; Di Martino V; Thibaut V; Salmon D; Ziol M; Sutton A; Pol S; Roudot-Thoraval F;
Gastroenterology; 2017 Jan; 152(1):142-156.e2. PubMed ID: 27641509
[TBL] [Abstract][Full Text] [Related]
20. Effect of coexisting diabetes mellitus and chronic kidney disease on mortality of cirrhotic patients with esophageal variceal bleeding.
Lung CC; Jian ZH; Huang JY; Nfor ON
BMC Gastroenterol; 2016 Feb; 16():29. PubMed ID: 26924648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
